IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence ...

Fintel reports that on April 25, 2025, HSBC downgraded their outlook for IQVIA Holdings (NYSE:IQV) from Buy to Hold. Analyst ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $227.67, ...

With a market cap of $25.4 billion, IQVIA Holdings Inc. (IQV) provides clinical research services, commercial insights, and ...

Comac Medical, a full-service contract research organization (CRO) based in Bulgaria, has announced major leadership changes ...

The stock's rise snapped a four-day losing streak.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm ...

Today's appointments mark a significant milestone for Comac Medical as it enters its next phase of development, building upon the recent additions of two seasoned industry leaders based in Germany, ...

HSBC analyst Sidharth Sahoo downgraded Iqvia (IQV) to Hold from Buy with a price target of $160, down from $260. The firm adjusted ratings in ...

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

IQVIA Hldgs (NYSE:IQV) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed ...